Principal Technologies (FRA:JO7) Cyclically Adjusted PS Ratio: (As of Jul. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:JO7 Principal Technologies Inc FRA:JO7
12 GF Score
Price €0.20
GF Value €0.04
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Principal Technologies Cyclically Adjusted PS Ratio?

Principal Technologies does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


Principal Technologies  (FRA:JO7) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Principal Technologies Cyclically Adjusted PS Ratio Related Terms


Principal Technologies Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Principal Technologies's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Principal Technologies Cyclically Adjusted PS Ratio Chart

Principal Technologies Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Principal Technologies Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:JO7 vs VEEV, BTSG, TEM: Cyclically Adjusted PS Ratio Comparison

For the Health Information Services subindustry, Principal Technologies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Principal Technologies Cyclically Adjusted PS Ratio vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Principal Technologies's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Principal Technologies's Cyclically Adjusted PS Ratio falls into.


FRA:JO7
12GF Score
Principal Technologies Inc FRA:JO7
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Principal Technologies Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Principal Technologies does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Is Principal Technologies (FRA:JO7) Overvalued in 2026?

Based on GuruFocus' analysis, Principal Technologies stock appears to be overvalued. The current stock price of €0.20 is trading 395% above its estimated GF Value™ of €0.04. GuruFocus considers Principal Technologies to be Significantly Overvalued.

Key valuation signals for FRA:JO7:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €0.04 vs. price of €0.20 (395% above fair value)
  • GF Score™: 12/100 with 7 warning signs

No single metric tells the full story. See the FRA:JO7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Principal Technologies Business Description

Other Exchanges PTEC:Canada
Address 700 West Georgia Street, Suite 2500, Vancouver, BC, CAN, V7Y 1B3
Principal Technologies Inc is in the research and development stage of building a portfolio of medical technology assets with a focus on distribution potential and intellectual property capable of enhancing medical treatment, cost efficiency, and optimization of the patient pathway. The company focuses on acquiring medical technology research and development assets or developing them jointly with industry leaders. Its current revenue-generating activities are attributable to E&E CRO Consulting GmbH, which provides clinical research advisory services. The company operates in one reportable operational segment, consisting of project management of clinical studies and research related to medical device technologies.
12GF Score

Get the complete analysis for FRA:JO7

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price
€0.04
GF Value